查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
抗病毒藥物的全球市場(2022年～2028年)
市場調查報告書
商品編碼
1215701

抗病毒藥物的全球市場(2022年～2028年)

Anti-Viral Drug Market 2022-2028
出版日期: | 出版商: Orion Market Research | 英文 | 商品交期: 2-3個工作天內

價格

全球抗病毒藥物的市場規模，在預測期間內預計以4.0％的年複合成長率成長。

由於感染疾病的流行增加，需求和生產都以更廣泛的等級劇增。還有製藥公司的持續性研究開發與開發新藥的投資，擴大市場成長的新可能性。再加上病毒感染疾病治療藥物的FDA核準高漲，也考慮為市場發展的突出方面之一 。

本報告提供全球抗病毒藥物市場相關調查分析，市場概要，各市場區隔、地區的市場分析，競爭情形，企業簡介等系統性資訊。

目錄

第1章 報告概要

第2章 市場概要與洞察

  • 調查範圍
  • 分析師的洞察和目前市場趨勢
  • 波特分析

第3章 競爭情形

  • 主要企業分析
    • 概要
    • 財務分析
    • SWOT分析
    • 最近的開發
  • 主要策略分析

第4章 市場明細

  • 全球抗病毒藥物市場:各類型
    • 非專利
    • 品牌
  • 全球抗病毒藥物市場:各作用機制
    • 核甘酸聚合酵素抑制劑
    • 逆轉錄酵素抑制劑
    • 蛋白分解酵素抑制劑
    • 其他
  • 全球抗病毒藥物市場:各用途
    • HIV
    • 肝炎
    • 皰疹病毒
    • 流感
    • 其他

第5章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 其他地區
    • 南美
    • 中東、非洲

第6章 企業簡介

  • AbbVie, Inc.
  • Abbott Laboratories
  • Arbutus Biopharma Corp.
  • Aurobindo Pharma, Ltd.
  • BioCryst Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Co.
  • Candel Therapeutics, Inc.
  • Cipla, Inc.
  • Dr. Reddy's Laboratories, Ltd.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Pfizer, Inc.
  • Sanofi S.A.
  • Sino Biopharmaceutical, Ltd.
  • The Hep B Company
  • Zydus Lifesciences, Ltd.
Product Code: OMR2026757

Title:Global Anti-Viral Drug Market Size, Share, and Trends Analysis Report, by Type (Generic Anti-Viral Drugs and Branded Anti-Viral Drugs), by Mechanism of Action (Nucleotide Polymerase Inhibitor, Reverse Transcriptase Inhibitors, Protease Inhibitors, and Others), by Application (HIV, Hepatitis, Herpes Virus, Influenza, and Others), Forecast Period (2022-2028).

The global anti-viral drug market is anticipated to grow at a CAGR of 4.0% during the forecast period. The anti-viral drugs have found their effective use in the treatment of viral infections, such as hepatitis, HIV, influenza, and others. The increased prevalence of these infections has surged both the demand as well as production on a wider level. Continuous R&D and investment by pharma companies in new drug development are opening a new path for market growth. Rising FDA approvals of the drug for the treatment of viral infection are also considered one of the prominent aspects of market development. For instance, in March 2022, GlaxoSmithKline Plc and Vir Biotechnology, Inc got approval from the USFDA for the Emergency Use Authorization (EUA) Fact Sheet for sotrovimab, an investigational monoclonal antibody due to Omicron BA.2 Subvariant. Moreover, in November 2019, the USFDA approved a supplemental New Drug Application for Roche's Xofluza for the treatment of influenza in patients 12 years of age and older. Likewise, in March 2019, GlaxoSmithKline Plc received approval from the National Medical Products Administration for Viread (tenofovir disoproxil fumarate), an oral antiviral drug for chronic hepatitis B treatment.

The global anti-viral drug market is segmented based on type, mechanism of action, and application. Based on type, the market is sub-segmented into generic anti-viral drugs and branded anti-viral drugs. Based on the mechanism of action, the market is further classified into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, and others. Similarly, based on application, it is classified into HIV, hepatitis, herpes virus, influenza, and others.

Geographically, the anti-viral drug market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. The Asia-Pacific region is anticipated to exhibit a high CAGR during the forthcoming period. Growth is attributable to the frequent outbursts of viral diseases, namely, swine flu, dengue, and Ebola in emerging economies. The increasing number of generic pharmaceutical companies present in this region would contribute to the growth. Moreover, the increasing incidence of viral infection and surging approval and expected commercialization of novel medicines for viral infections are the crucial factors anticipated to drive the North American anti-viral drug market growth during the forecast period.

The major market players in the global anti-viral drug market include AbbVie, Inc., Merck & Co., GlaxoSmithKline plc, Pfizer Inc., Mylan NV, Dr. Reddy's Laboratories Ltd., Apotex Inc., Teva Pharmaceutical Industries Ltd., Cipla Inc., Hikma Pharmaceuticals Ltd., Strides Pharma Science Ltd., Upsher-Smith Laboratories, among others. The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market.

Research Methodology

The market study of the global anti-viral drug is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of the market size and intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Anti-Viral Drug Research and Analysis by Type
  • Global Anti-Viral Drug Research and Analysis by Mechanism of Action
  • Global Anti-Viral Drug Research and Analysis by Application

The Report Covers:

  • Comprehensive research methodology of the global anti-viral drug market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global anti-viral drug market.
  • Insights about market determinants that are stimulating the global anti-viral drug market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Porter's Analysis

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Anti-Viral Drug Market by Type
    • 4.1.1. Generic Anti-Viral Drugs
    • 4.1.2. Branded Anti-Viral Drugs
  • 4.2. Global Anti-Viral Drug Market by Mechanism of Action
    • 4.2.1. Nucleotide Polymerase Inhibitor
    • 4.2.2. Reverse Transcriptase Inhibitors
    • 4.2.3. Protease Inhibitors
    • 4.2.4. Others
  • 4.3. Global Anti-Viral Drug Market by Application
    • 4.3.1. HIV
    • 4.3.2. Hepatitis
    • 4.3.3. Herpes Virus
    • 4.3.4. Influenza
    • 4.3.5. Others

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World
    • 5.4.1. Latin America
    • 5.4.2. Middle East & Africa

6. Company Profiles

  • 6.1. AbbVie, Inc.
  • 6.2. Abbott Laboratories
  • 6.3. Arbutus Biopharma Corp.
  • 6.4. Aurobindo Pharma, Ltd.
  • 6.5. BioCryst Pharmaceuticals, Inc.
  • 6.6. Bristol-Myers Squibb Co.
  • 6.7. Candel Therapeutics, Inc.
  • 6.8. Cipla, Inc.
  • 6.9. Dr. Reddy's Laboratories, Ltd.
  • 6.10. F. Hoffmann-La Roche AG
  • 6.11. Gilead Sciences, Inc.
  • 6.12. GlaxoSmithKline PLC
  • 6.13. Johnson & Johnson Services, Inc.
  • 6.14. Merck & Co., Inc.
  • 6.15. Mylan N.V.
  • 6.16. Pfizer, Inc.
  • 6.17. Sanofi S.A.
  • 6.18. Sino Biopharmaceutical, Ltd.
  • 6.19. The Hep B Company
  • 6.20. Zydus Lifesciences, Ltd.

LIST OF TABLES

  • 1. GLOBAL ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 2. GLOBAL GENERIC ANTI-VIRAL DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL BRANDED ANTI-VIRAL DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 5. GLOBAL ANTI-VIRAL DRUG IN HIV MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL ANTI-VIRAL DRUG IN HEPATITIS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 7. GLOBAL ANTI-VIRAL DRUG IN HERPES VIRUS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. GLOBAL ANTI-VIRAL DRUG IN INFLUENZA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 9. GLOBAL ANTI-VIRAL DRUG IN OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY MECHANISM OF ACTION, 2021-2028 ($ MILLION)
  • 11. GLOBAL NUCLEOTIDE POLYMERASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 12. GLOBAL REVERSE TRANSCRIPTASE INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 13. GLOBAL PROTEASE INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 14. GLOBAL OTHER MECHANISM OF ACTION MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 15. GLOBAL ANTI-VIRAL DRUG IN INFLUENZA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 16. GLOBAL ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 17. NORTH AMERICAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 18. NORTH AMERICAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 19. NORTH AMERICAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY MECHANISM OF ACTION, 2021-2028 ($ MILLION)
  • 20. NORTH AMERICAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 21. EUROPEAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 22. EUROPEAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 23. EUROPEAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY MECHANISM OF ACTION, 2021-2028 ($ MILLION)
  • 24. EUROPEAN ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 25. ASIA-PACIFIC ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 26. ASIA-PACIFIC ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 27. ASIA-PACIFIC ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY MECHANISM OF ACTION, 2021-2028 ($ MILLION)
  • 28. ASIA-PACIFIC ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 29. REST OF THE WORLD ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 30. REST OF THE WORLD ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 31. REST OF THE WORLD ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY MECHANISM OF ACTION, 2021-2028 ($ MILLION)
  • 32. REST OF THE WORLD ANTI-VIRAL DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL ANTI-VIRAL DRUG MARKET SHARE BY TYPE, 2021 VS 2028 (%)
  • 2. GLOBAL ANTI-VIRAL DRUG MARKET SHARE BY MECHANISM OF ACTION, 2021 VS 2028 (%)
  • 3. GLOBAL ANTI-VIRAL DRUG MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
  • 4. GLOBAL ANTI-VIRAL DRUG MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 5. GLOBAL GENERIC ANTI-VIRAL DRUGS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 6. GLOBAL BRANDED ANTI-VIRAL DRUGS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 7. GLOBAL ANTI-VIRAL DRUG IN HIV MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 8. GLOBAL ANTI-VIRAL DRUG IN HEPATITIS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 9. GLOBAL ANTI-VIRAL DRUG IN HERPES VIRUS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 10. GLOBAL ANTI-VIRAL DRUG IN INFLUENZA MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 11. GLOBAL ANTI-VIRAL DRUG IN OTHER APPLICATIONS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 12. GLOBAL NUCLEOTIDE POLYMERASE INHIBITOR MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 13. GLOBAL REVERSE TRANSCRIPTASE INHIBITORS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 14. GLOBAL PROTEASE INHIBITORS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 15. GLOBAL OTHER MECHANISM OF ACTION MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 16. GLOBAL ANTI-VIRAL DRUG IN INFLUENZA MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 17. US ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 18. CANADA ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 19. UK ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 20. FRANCE ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. GERMANY ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. ITALY ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. SPAIN ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 24. REST OF EUROPE ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 25. INDIA ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 26. CHINA ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 27. JAPAN ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 28. SOUTH KOREA ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 29. REST OF ASIA-PACIFIC ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 30. REST OF THE WORLD ANTI-VIRAL DRUG MARKET SIZE, 2021-2028 ($ MILLION)